Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests, today announced that Dr. Klaus
Paulini, Chief Executive Officer of Aeterna, will present at the
virtual H.C. Wainwright Global Life Sciences Conference taking
place March 9-10, 2021.
The video webcast presentation will be available
for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM
ET for those registered for the event and will be accessible on the
Events page in the Investors section of the Company’s website
(www.zentaris.com). The webcast replay will be archived for 90 days
following the event.
For more information about the conference,
please visit the conference website here.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
macimorelin, is the first and only U.S. FDA and European Commission
approved oral test indicated for the diagnosis of adult growth
hormone deficiency (AGHD). Macimorelin is currently marketed in the
United States under the tradename Macrilen™ through a license
agreement with Novo Nordisk where Aeterna receives royalties on net
sales. According to a commercialization and supply agreement,
MegaPharm Ltd. will seek regulatory approval and then commercialize
macimorelin in Israel and the Palestinian Authority. Additionally,
upon receipt of pricing and reimbursement approvals, Aeterna
expects that macimorelin will be marketed in Europe and the United
Kingdom through a recently established license agreement with
Consilient Health Ltd. and Aeterna will receive royalties on net
sales and other potential payments.
The Company is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of childhood-onset growth hormone deficiency
(CGHD), an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Asia and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the
Company on Twitter, LinkedIn and Facebook.
This press release contains forward-looking
statements (as defined by applicable securities legislation) made
pursuant to the safe-harbor provision of the U.S. Securities
Litigation Reform Act of 1995, which reflect our current
expectations regarding future events. Forward-looking statements in
this press release include those relating to Aeterna’s expectation
that, upon receipt of pricing and reimbursement approvals,
macimorelin will be marketed in Europe and the United Kingdom.
Forward-looking statements involve known and unknown risks and
uncertainties, and other factors which may cause the actual
results, performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, our ability to obtain receipt of pricing and
reimbursement approvals as well as those risks discussed in our
Annual Report on Form 20-F, under the caption "Key Information
-Risk Factors" filed with the relevant Canadian securities
regulatory authorities in lieu of an annual information form and
with the U.S. Securities and Exchange Commission. Given the
uncertainties and risk factors, readers are cautioned not to place
undue reliance on these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce any
revisions to any of the forward-looking statements contained herein
to reflect future results, events or developments, unless required
to do so by a governmental authority or applicable law.
Investor Contact: Jenene Thomas JTC Team T
(US): +1 (833) 475-8247 E: email@example.com